Revised Financial Forecast for the Fiscal Year Ending December 31, 2026
Filed with TSE · · 3 pages · English
In the deck
Story so far
Earlier from Veritas In Silico
- Monthly Status of Exercise of #5 (with Exercise Price Adjustment Clause) and #6 to #9 Share Acquisition Rights(with Target Issue and Adjustment Optio
- Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted Compounds
- Notice of Completion of Payment for #5 and #6 to #9 Share Acquisition Rights by Third-Party Allotment
- Notice Concerning Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc.
- Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP]
Later from Veritas In Silico
All Veritas In Silico news releasesFollow Veritas In Silico into a list and get an email when it puts out news.
Follow Veritas In Silico